2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association

다국어 초록 (Multilingual Abstract)

The Committee of Clinical Practice Guidelines of the Korean Diabetes Association (KDA) updated the previous clinical practice guidelines for Korean adults with diabetes and prediabetes and published the seventh edition in May 2021. We performed a comprehensive systematic review of recent clinical trials and evidence that could be applicable in real-world practice and suitable for the Korean population. The guideline is provided for all healthcare providers including physicians, diabetes experts, and certified diabetes educators across the country who manage patients with diabetes or the individuals at the risk of developing diabetes mellitus. The recommendations for screening diabetes and glucose-lowering agents have been revised and updated. New sections for continuous glucose monitoring, insulin pump use, and non-alcoholic fatty liver disease in patients with diabetes mellitus have been added. The KDA recommends active vaccination for coronavirus disease 2019 in patients with diabetes during the pandemic. An abridgement that contains practical information for patient education and systematic management in the clinic was published separately.

참고문헌 (Reference)

• 1 Bell KJ, "a systematic review and meta-analysis" 2 : 133-140, 2014
• 2 Buse JB, "Use of twice-daily exenatide in basal insulintreated patients with type 2 diabetes : a randomized, controlled trial" 154 : 103-112, 2011
• 3 Rodbard HW, "Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy(FullSTEP Study) : a randomised, treat-to-target clinical trial" 2 : 30-37, 2014
• 4 Korean Diabetes Association, "Treatment guideline for diabetes"
• 5 DAFNE Study Group, "Training in flexible, intensive insulin management to enable dietary freedom in people with type 1diabetes : dose adjustment for normal eating(DAFNE)randomised controlled trial" 325 : 746-, 2002
• 6 UK Prospective Diabetes Study Group, "Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes : UKPDS 38. UK Prospective Diabetes Study Group" 317 : 703-713, 1998
• 7 Musso G, "Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis : a meta-analysis" 177 : 633-640, 2017
• 8 Hingorani A, "The management of diabetic foot : a clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine" 63 (63): 3-, 2016
• 9 Linjawi S, "The efficacy of IDegLira(insulin degludec/liraglutide combination)in adults with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist and oral therapy : DUAL III Randomized Clinical Trial" 8 : 101-114, 2017
• 10 Diabetes Control, "The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus" 329 : 977-986, 1993
• 11 "The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus:the diabetes control and complications trial" 113 : 36-51, 1995
• 12 Lewis EJ, "The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group" 329 : 1456-1462, 1993
• 13 Chalasani N, "The diagnosis and management of nonalcoholic fatty liver disease : practice guidance from the American Association for the Study of Liver Diseases" 67 : 328-357, 2018
• 14 Brugts JJ, "The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials" 338 : b2376-, 2009
• 15 Lee AK, "The association of severe hypoglycemia with incident cardiovascular events and mortality in adults with type 2 diabetes" 41 : 104-111, 2018
• 16 Schectman JM, "The association between diabetes metabolic control and drug adherence in an indigent population" 25 : 1015-1021, 2002
• 17 Seyed Ahmadi S, "The association between HbA1c and time in hypoglycemia during CGM and self-monitoring of blood glucose in people with type 1 diabetes and multiple daily insulin injections : a randomized clinical trial(GOLD-4)" 43 : 2017-2024, 2020
• 18 Ramachandran A, "The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance(IDPP-1)" 49 : 289-297, 2006
• 19 Blonde L, "Switching to iGlarLixi versus continuing daily or weekly GLP-1 RA in type 2 diabetes inadequately controlled by GLP-1 RA and oral antihyperglycemic therapy : the LixiLan-G Randomized Clinical Trial" 42 : 2108-2116, 2019
• 20 Little SA, "Sustained reduction in severe hypoglycemia in adults with type 1 diabetes complicated by impaired awareness of hypoglycemia : two-year follow-up in the HypoCOMPaSS randomized clinical trial" 41 : 1600-1607, 2018
• 21 Vigersky RA, "Short-and long-term effects of real-time continuous glucose monitoring in patients with type 2 diabetes" 35 : 32-38, 2012
• 22 Melo KF, "Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus : a systematic review and meta-analysis" 11 : 2-, 2019
• 23 이진희, "Short-Term Effects of the Internet-Based Korea Diabetes Prevention Study: 6-Month Results of a Community-Based Randomized Controlled Trial" 대한당뇨병학회 45 (45): 960-965, 2021
• 24 DeVries JH, "Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets" 35 : 1446-1454, 2012
• 25 Marso SP, "Semaglutide and cardiovascular outcomes in patients with type 2 diabetes" 375 : 1834-1844, 2016
• 26 Rodbard HW, "Semaglutide added to basal insulin in type 2 diabetes(SUSTAIN 5) : a randomized, controlled trial" 103 : 2291-2301, 2018
• 27 Cohen R, "Roux-en-Y gastric bypass in type 2 diabetes patients with mild obesity : a systematic review and meta-analysis" 27 : 2733-2739, 2017
• 28 Mauer M, "Renal and retinal effects of enalapril and losartan in type 1 diabetes" 361 : 40-51, 2009
• 29 Knowler WC, "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin" 346 : 393-403, 2002
• 30 Heinemann L, "Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections(HypoDE) : a multicentre, randomised controlled trial" 391 : 1367-1377, 2018
• 31 Seino Y, "Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea(GetGoal-L-Asia)" 14 : 910-917, 2012
• 32 Colhoun HM, "Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study(CARDS) : multicentre randomised placebo-controlled trial" 364 : 685-696, 2004
• 33 Lean ME, "Primary care-led weight management for remission of type 2 diabetes(DiRECT) : an open-label, clusterrandomised trial" 391 : 541-551, 2018
• 34 Tuomilehto J, "Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance" 344 : 1343-1350, 2001
• 35 The Diabetic Retinopathy Study Research Group, "Preliminary report on effects of photocoagulation therapy" 81 : 383-396, 1976
• 36 Forlenza GP, "Predictive low-glucose suspend reduces hypoglycemia in adults, adolescents, and children with type 1 diabetes in an at-home randomized crossover study : results of the PROLOG trial" 41 : 2155-2161, 2018
• 37 Pozzilli P, "Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2diabetes(AWARD-9)" 19 : 1024-1031, 2017
• 38 Finnerup NB, "Pharmacotherapy for neuropathic pain in adults : a systematic review and meta-analysis" 14 : 162-173, 2015
• 39 Waldfogel JM, "Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life : a systematic review" 88 : 1958-1967, 2017
• 40 Yeo D, "Outcomes after metabolic surgery in asians-a meta-analysis" 29 : 114-126, 2019
• 41 Gough SC, "One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes : results of a 26-week extension to a 26-week main trial" 17 : 965-973, 2015
• 42 Blonde L, "Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes(AWARD-4) : a randomised, open-label, phase 3, non-inferiority study" 385 : 2057-2066, 2015
• 43 Wheeler ML, "Macronutrients, food groups, and eating patterns in the management of diabetes : a systematic review of the literature, 2010" 35 : 434-445, 2012
• 44 Heart Protection Study Collaborative Group, "MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals : a randomised placebocontrolled trial" 360 : 7-22, 2002
• 45 Laranjeira FO, "Long-acting insulin analogues for type 1 diabetes : an overview of systematic reviews and meta-analysis of randomized controlled trials" 13 : e0194801-, 2018
• 46 유순집, "Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus" 대한당뇨병학회 45 (45): 954-959, 2021
• 47 Russell-Jones D, "Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus(LEAD-5 met+SU) : a randomised controlled trial" 52 : 2046-2055, 2009
• 48 Armstrong MJ, "Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis(LEAN) : a multicentre, double-blind, randomised, placebo-controlled phase 2 study" 387 : 679-690, 2016
• 49 Marso SP, "Liraglutide and cardiovascular outcomes in type 2 diabetes" 375 : 311-322, 2016
• 50 Levin A, "KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease" 3 : 1-150, 2013
• 51 Lankisch MR, "Introducing a simplified approach to insulin therapy in type 2 diabetes : a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs" 10 : 1178-1185, 2008
• 52 Buckley LF, "Intensive versus standard blood pressure control in SPRINT-eligible participants of ACCORD-BP" 40 : 1733-1738, 2017
• 53 Ohkubo Y, "Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study" 28 : 103-117, 1995
• 54 Nathan DM, "Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes" 353 : 2643-2653, 2005
• 55 UK Prospective Diabetes Study (UKPDS) Group, "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)" 352 : 837-853, 1998
• 56 Ana Chico, "Intensive Insulin Therapy (Basal-Bolus)" Ovid Technologies (Wolters Kluwer Health) 29 (29): e64-e73, 2020
• 57 Leahy JL, "Insulin therapy in type 2 diabetes mellitus" 41 : 119-144, 2012
• 58 Reznik Y, "Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes(OpT2mise) : a randomised open-label controlled trial" 384 : 1265-1272, 2014
• 59 Aschner P, "Insulin glargine compared with premixed insulin for management of insulin-naïve type 2 diabetes patients uncontrolled on oral antidiabetic drugs : the open-label, randomized GALAPAGOS study" 29 : 838-845, 2015
• 60 Jin-Hee Lee, "Impaired fasting glucose levels in overweight or obese subjects for screening of type 2 diabetes in Korea" 대한내과학회 36 (36): 382-391, 2021
• 61 이상열, "Hospital-Based Korean Diabetes Prevention Study: A Prospective, Multi-Center, Randomized, Open-Label Controlled Study" 대한당뇨병학회 43 (43): 49-58, 2019
• 62 Matthews DR, "Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes(VERIFY) : a 5-year, multicentre, randomised, doubleblind trial" 394 : 1519-1529, 2019
• 63 Hayward RA, "Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes" 372 : 2197-2206, 2015
• 64 Cannon CP, "Ezetimibe added to statin therapy after acute coronary syndromes" 372 : 2387-2397, 2015
• 65 Heine RJ, "Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes : a randomized trial" 143 : 559-569, 2005
• 66 Davies MJ, "Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes : results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin(HEELA)study" 11 : 1153-1162, 2009
• 67 Sabatine MS, "Evolocumab and clinical outcomes in patients with cardiovascular disease" 376 : 1713-1722, 2017
• 68 Zinman B, "Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes" 373 : 2117-2128, 2015
• 69 Wanner C, "Empagliflozin and progression of kidney disease in type 2 diabetes" 375 : 323-334, 2016
• 70 Wanner Ch, "Empagliflozin and progression of kidney disease in type 2 diabetes" 375 : 1801-1802, 2016
• 71 Kaku K, "Empagliflozin and cardiovascular outcomes in asian patients with type 2 diabetes and established cardiovascular disease : results from EMPA-REG OUTCOME" 81 : 227-234, 2017
• 72 Davies MJ, "Efficacy of liraglutide for weight loss among patients with type 2 diabetes : the SCALE diabetes randomized clinical trial" 314 : 687-699, 2015
• 73 Cholesterol Treatment Trialists’(CTT)Collaborators, "Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins : a meta-analysis" 371 : 117-125, 2008
• 74 Aroda VR, "Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin(with or without sulfonylureas)in insulin-naive patients with type 2diabetes(SUSTAIN 4) : a randomised, open-label, parallelgroup, multicentre, multinational, phase 3a trial" 5 : 355-366, 2017
• 75 Giorgino F, "Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride(AWARD-2)" 38 : 2241-2249, 2015
• 76 Araki E, "Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes : a randomized, open-label, phase III, non-inferiority study" 17 : 994-1002, 2015
• 77 Yang W, "Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin : the GetGoal-L-C randomized trial" 20 : 335-343, 2018
• 78 Rosenstock J, "Efficacy and safety of lixilan, a titratable fixedratio combination of lixisenatide and insulin glargine, versus insulin glargine in type 2 diabetes inadequately controlled on metformin monotherapy : the lixilan proof-of-concept randomized trial" 39 : 1579-1586, 2016
• 79 Aroda VR, "Efficacy and safety of lixilan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin : the LixiLan-L randomized trial" 39 : 1972-1980, 2016
• 80 Ahmann A, "Efficacy and safety of liraglutide versus placebo added to basal insulin analogues(with or without metformin)in patients with type 2 diabetes : a randomized, placebo-controlled trial" 17 : 1056-1064, 2015
• 81 Gough SC, "Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide(IDegLira)compared with its components given alone : results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes" 2 : 885-893, 2014
• 82 Cholesterol Treatment Trialists’(CTT)Collaboration, "Efficacy and safety of LDL-lowering therapy among men and women : meta-analysis of individual data from 174, 000 participants in 27 randomised trials" 385 : 1397-1405, 2015
• 83 Heart Outcomes Prevention Evaluation Study Investigators, "Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus : results of the HOPE study and MICRO-HOPE substudy" 355 : 253-259, 2000
• 84 Pop-Busui R, "Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus : the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study(DCCT/EDIC)" 119 : 2886-2893, 2009
• 85 Hollander P, "Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes" 36 : 4022-4029, 2013
• 86 Gadde KM, "Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults(CONQUER) : a randomised, placebo-controlled, phase 3 trial" 377 : 1341-1352, 2011
• 87 Brenner BM, "Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy" 345 : 861-869, 2001
• 88 ACCORD Study Group, "Effects of intensive bloodpressure control in type 2 diabetes mellitus" 362 : 1575-1585, 2010
• 89 Hansson L, "Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension : principal results of the Hypertension Optimal Treatment(HOT)randomised trial. HOT Study Group" 351 : 1755-1762, 1998
• 90 Owens DR, "Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2diabetes : a 6-month ‘proof-of-concept’ study" 13 : 1020-1027, 2011
• 91 Turnbull F, "Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus : results of prospectively designed overviews of randomized trials" 165 : 1410-1419, 2005
• 92 Pan XR, "Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance : the Da Qing IGT and Diabetes Study" 20 : 537-544, 1997
• 93 Chew EY, "Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus : Early Treatment Diabetic Retinopathy Study report no. 20" 113 : 52-55, 1995
• 94 Bergenstal RM, "Effectiveness of sensor-augmented insulinpump therapy in type 1 diabetes" 363 : 311-320, 2010
• 95 Diabetes Control, "Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group" 23 : 1084-1091, 2000
• 96 Writing Team for the Diabetes Control, "Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus" 287 : 2563-2569, 2002
• 97 Lingvay I, "Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes : the DUAL V Randomized Clinical Trial" 315 : 898-907, 2016
• 98 Battelino T, "Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes" 34 : 795-800, 2011
• 99 Aroda VR, "Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide : a double-blind randomized controlled trial(BEGIN : ADD TO GLP-1 Study)" 18 : 663-670, 2016
• 100 Rytter K, "Education programmes for persons with type 1diabetes using an insulin pump: a systematic review" 37 : e3412-, 2021
• 101 Gerstein HC, "Dulaglutide and cardiovascular outcomes in type 2 diabetes(REWIND) : a double-blind, randomised placebo-controlled trial" 394 : 121-130, 2019
• 102 Bangalore S, "Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers : systematic review and meta-analysis of randomized trials" 352 : i438-, 2016
• 103 정찬희, "Diabetes Fact Sheets in Korea, 2020: An Appraisal of Current Status" 대한당뇨병학회 45 (45): 1-10, 2021
• 104 Diabetes Canada Clinical Practice Guidelines Expert Committee, "Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome" 42 (42): S10-S15, 2018
• 105 Heerspink HJ, "Dapagliflozin in patients with chronic kidney disease" 383 : 1436-1446, 2020
• 106 Wiviott SD, "Dapagliflozin and cardiovascular outcomes in type 2 diabetes" 380 : 347-357, 2019
• 107 Buse JB, "Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide(IDegLira)" 37 : 2926-2933, 2014
• 108 Beck RW, "Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections : a randomized trial" 167 : 365-374, 2017
• 109 Feig DS, "Continuous glucose monitoring in pregnant women with type 1 diabetes(CONCEPTT) : a multicentre international randomised controlled trial" 390 : 2347-2359, 2017
• 110 Boulton AJ, "Comprehensive foot examination and risk assessment : a report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists" 31 : 1679-1685, 2008
• 111 윤건호, "Comparison of the Efficacy of Glimepiride, Metformin, and Rosiglitazone Monotherapy in Korean Drug-Naïve Type 2 Diabetic Patients: The Practical Evidence of Antidiabetic Monotherapy Study" 대한당뇨병학회 35 (35): 26-33, 2011
• 112 홍남기, "Comparison of the Effects of Ezetimibe-Statin Combination Therapy on Major Adverse Cardiovascular Events in Patients with and without Diabetes: A Meta-Analysis" 대한내분비학회 33 (33): 219-227, 2018
• 113 D’Alessio D, "Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes" 17 : 170-178, 2015
• 114 Tang W, "Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus : a systematic review and meta-analysis of randomized and nonrandomized studies" 32 : 200-216, 2016
• 115 Palmer SC, "Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease : a network meta-analysis" 385 : 2047-2056, 2015
• 116 Tsapas A, "Comparative effectiveness of glucose-lowering drugs for type 2 diabetes : a systematic review and network meta-analysis" 173 : 278-286, 2020
• 117 Yeh HC, "Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus : a systematic review and meta-analysis" 157 : 336-347, 2012
• 118 Battelino T, "Clinical targets for continuous glucose monitoring data interpretation : recommendations from the International Consensus on Time in Range" 42 : 1593-1603, 2019
• 119 Bakris GL, "Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study" 44 : 637-642, 2004
• 120 Arnold SV, "Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus : a scientific statement from the American Heart Association" 141 : e779-806, 2020
• 121 Cannon CP, "Cardiovascular outcomes with ertugliflozin in type 2 diabetes" 383 : 1425-1435, 2020
• 122 Berl T, "Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy" 138 : 542-549, 2003
• 123 Lindholm LH, "Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension Study(LIFE) : a randomised trial against atenolol" 359 : 1004-1010, 2002
• 124 Look AHEAD Research Group, "Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes" 369 : 145-154, 2013
• 125 Packer M, "Cardiovascular and renal outcomes with empagliflozin in heart failure" 383 : 1413-1424, 2020
• 126 Powers AC, "COVID-19 vaccine prioritisation for type 1 and type 2 diabetes" 9 : 140-141, 2021
• 127 Rosenstock J, "Benefits of lixilan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents : the LixiLan-O Randomized Trial" 39 : 2026-2035, 2016
• 128 Koutoukidis DA, "Association of weight loss interventions with changes in biomarkers of nonalcoholic fatty liver disease : a systematic review and meta-analysis" 179 : 1262-1271, 2019
• 129 Writing Group for the DCCT/EDIC Research Group, "Association between 7 years of intensive treatment of type 1diabetes and long-term mortality" 313 : 45-53, 2015
• 130 Sanchez-Hernandez RM, "Assessment of Alimentacion Normal con Ajuste de Insulina(ANAIS), a Spanish version of the DAFNE programme, in people with type 1 diabetes : a randomized controlled parallel trial" 36 : 1037-1045, 2019
• 131 Schwartz GG, "Alirocumab and cardiovascular outcomes after acute coronary syndrome" 379 : 2097-2107, 2018
• 132 Holman RR, "Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes" 357 : 1716-1730, 2007
• 133 Riddle MC, "Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine : a 24-week, randomized, placebo-controlled study(GetGoal-Duo 1)" 36 : 2497-2503, 2013
• 134 Riddle MC, "Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin : a 24-week, randomized, placebo-controlled comparison(GetGoal-L)" 36 : 2489-2496, 2013
• 135 Oh JY, "A report on the diagnosis of intermediate hyperglycemia in Korea : a pooled analysis of four community-based cohort studies" 80 : 463-468, 2008
• 136 SPRINT Research Group, "A randomized trial of intensive versus standard blood-pressure control" 373 : 2103-2116, 2015
• 137 Saudek CD, "A new look at screening and diagnosing diabetes mellitus" 93 : 2447-2453, 2008
• 138 Kasiske BL, "A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function" 31 : 954-961, 1998
• 139 김보연, "2020 Korean Society for the Study of Obesity Guidelines for the Management of Obesity in Korea" 대한비만학회 30 (30): 81-92, 2021
• 140 김미경, "2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea" 대한당뇨병학회 43 (43): 398-406, 2019
• 141 고승현, "2011 Clinical Practice Guidelines for Type 2 Diabetes in Korea" 대한당뇨병학회 35 (35): 431-436, 2011
• 142 American Diabetes Association, "2. Classification and diagnosis of diabetes : standards of medical care in diabetes-2018" 41 (41): S13-27, 2018
• 143 American Diabetes Association, "10. Cardiovascular disease and risk management : standards of medical care in diabetes-2020" 43 (43): S111-34, 2020
• 144 Holman RR, "10-Year follow-up of intensive glucose control in type 2 diabetes" 359 : 1577-1589, 2008